EUPHORIA Blend for Women: Desire, the Cycle, Menopause and What the Research Covers

A 2007 paper in the Journal of Clinical Endocrinology and Metabolism reported that the LH response to subcutaneous kisspeptin-54 in healthy women varied across the cycle and was greatest in the days before ovulation. A 2011 study reported that kisspeptin's effect differed between men and women, which is one reason findings in men, where most of the hormone studies were done, do not transfer directly.

In women whose periods had stopped because of low body weight, stress or over-training, twice-daily subcutaneous kisspeptin-54 for two weeks stimulated the axis and then the response faded (JCEM, 2009), while twice-weekly injections for eight weeks sustained it (Clinical Pharmacology and Therapeutics, 2010). That fading under continuous exposure is why EUPHORIA's schedule has weekends off. These were small physiological studies; they did not measure whether ovulation, periods or fertility returned.

A 2014 paper in the Journal of Clinical Investigation reported that a single subcutaneous kisspeptin-54 injection, given in place of the usual trigger to women undergoing IVF, produced egg maturation in the large majority and was followed by live births, with follow-up trials in 2015 and 2017. Those were one- or two-dose triggers inside monitored fertility cycles. EUPHORIA is not a fertility treatment.

A randomised, double-blind, placebo-controlled crossover trial in JAMA Network Open enrolled premenopausal women with hypoactive sexual desire disorder. A kisspeptin-54 infusion increased activation in sexual-processing brain regions on functional MRI, with no serious adverse events attributed to it. It was small, single-session and intravenous, and it measured brain response, not months of desire. A EUPHORIA dose carries 0.1 mg of subcutaneous kisspeptin-10. For comparison, PT-141 has two phase 3 trials in 1,267 premenopausal women with HSDD; see PT-141 for women and kisspeptin for women.

Ovariectomy is a standard animal model of post-menopausal metabolic change, which is why these studies are quoted for women. A 2019 paper in the Journal of Molecular Medicine reported less fat accumulation and more brown-fat activity in ovariectomised mice given MOTS-c, and a 2016 paper in Biochemical and Biophysical Research Communications reported less bone loss on micro-CT. Both describe prevention in mice, not change in women. There is no human trial of MOTS-c in either sex. See MOTS-c for women.

GHK-Cu's human studies are small cosmetic studies of topical GHK-Cu on photoaged facial skin, mostly in women, plus one topical gel study in diabetic ulcers. None used the injectable form, whose evidence is animal work. Whether injected GHK-Cu does for skin what creams are reported to do has not been tested.

BPC-157 has no sex-specific research. Its largest literature is animal work on the gut lining and on tendon and muscle injury, with early-phase human work for inflammatory bowel indications.

EUPHORIA is not used in pregnancy, breastfeeding or when trying to conceive. Kisspeptin acts directly on the reproductive axis, and none of the four components has human pregnancy or lactation safety data. If you are trying to conceive or in an IVF cycle, raise kisspeptin with the physician managing that care first. If you become pregnant on treatment, stop and contact your physician the same day. See can you take peptides while pregnant and do peptides affect fertility.

Kisspeptin acts on the axis that runs the cycle, and no trial has looked at what a weekday course does to cycle regularity or to hormonal contraception. Tell your physician which method you use, and report any change in your periods to your care team. If you are also on tirzepatide, its label notes reduced oral contraceptive absorption around dose changes; see can you take EUPHORIA blend with tirzepatide.

Because kisspeptin stimulates sex-hormone production, a hormone-sensitive condition, including a history of hormone-sensitive cancer, must be raised with your physician before starting.

No study of any EUPHORIA component enrolled women in the transition or after it for menopause symptoms. EUPHORIA is not hormone therapy and does not replace the hormones that change. Low desire in these years is often driven by dryness, pain, sleep and mood rather than central drive, and no desire peptide addresses dryness or pain. Pepti does not prescribe menopausal hormone therapy; see peptides for menopause and peptides for women.

SSRIs and SNRIs, a new medication, sleep, pain with sex and relationship context all come before a peptide; see peptides for libido. In women, iron deficiency and thyroid disease are common, findable causes of fatigue and are worth checking first.

EUPHORIA is prohibited for every athlete in a tested pool, women included. Kisspeptin's WADA class, S2.2.1, is worded for males, but EUPHORIA also contains MOTS-c and BPC-157, both prohibited at all times for everyone. See is EUPHORIA blend banned in sports.